Participants
| Role | Name | HCID | Charge |
|---|
| Reactant | Hydrochloric Acid | HCID 313 | — |
| Reactant | Sodium Hydroxide | HCID 14798 | — |
| Reactant | Erlotinib Impurity 14 | HCID 9868438 | — |
| Solvent | Isopropanol | HCID 3776 | — |
| Product | Erlotinib Hydrochloride | HCID 176871 | — |
Reaction Steps
4-[3-[[6,7-Bis(2-methoxyethoxy]-4-quinazolinyl]amino]phenyl]-2-methyl-3-butyn-2-ol, prepared above (20.0 g, 44.3 mmol), anhydrous solid sodium hydroxide (260 mg, 6.5 mmol) and propan-2-ol (200 mL) were stirred together and heated in a pressure vessel at 135-140° C. for 23 hours. The reaction mixture was cooled to 60-65° C. and concentrated hydrochloric acid (4.8 mL) was added. The resultant mixture was granulated overnight at 20-25° C. to establish crystallization. The mixture was treated with water (10 mL) and stirred at 58-60° C. for 21 hours, cooled to 15-20° C. and granulated for 2 hours. The title product crystals were isolated by filtration, washed with propan-2-ol (2×30 mL) and dried under vacuum at 45-50° C. to remove propan-2-ol. Yield (17.6 g, 92%).
Provenance & Evidence
| DOI | 10.6084/m9.figshare.5104873.v1 |
|---|
| Patent number | US06476040B1 |
|---|
| Source dataset | uspto-grants-2002_11 |
|---|
| ORD ID | ord-0bacad1d706c49edb9fb8dea8cea0d5f |
|---|
| Source note | uspto-grants-2002_11 |
|---|